Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0017638 (glioma)
 30,880 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There is considerable chemical and structural similarity between the widely used oncophilic substance pentavalent dimercaptosuccinic acid labeled with (99m)Tc [(99m)Tc-DMSA(V)] and the renal imaging agent trivalent [(99m)Tc-DMSA(III)]. Other renal imaging agents like diethyltriamine penta acetic acid (DTPA) and glucoheptonate labeled with (99m)Tc have been used for imaging brain lesions, mainly for brain tumor imaging. The aim of this study was to evaluate technetium labeled (99m)Tc-DMSA(III) for brain tumor imaging. Single photon emission computed tomography (SPECT) of the brain with (99m)Tc-DMSA(III) was performed in twenty-three patients with brain tumors in recurrence and the results were correlated with contrast enhanced magnetic resonance imaging (MRI) findings. Ten patients had multiform blioblastoma, 7 patients had anaplastic astocystoma, 5 patients low grade glioma and 1 patient menengioma. Our results show that brain SPECT was able to detect 20 of the 21 tumors detected by the contrast enhanced MRI of the brain. The brain scan was false positive in one patient. In two other patients two sites of radiation necrosis showed no tracer concentration. We conclude that (99m)Tc-DMSA(III) concentrates in recurrent brain tumors and can be used for the imaging of these tumors.
 ...
PMID:Imaging of recurrent brain tumors with trivalent (99m)Tc-dimercaptosuccinic acid - initial results. 1686 41

We compared pentavalent technetium-99m dimercaptosuccinic acid (Tc-99m (V) DMSA) brain single photon emission computed tomography (SPECT) and proton magnetic resonance spectroscopy ((1)H-MRS) for the detection of residual or recurrent gliomas after surgery and radiotherapy. A total of 24 glioma patients, previously operated upon and treated with radiotherapy, were studied. SPECT was acquired 2-3 h post-administration of 555-740 MBq of Tc-99m (V) DMSA. Lesion to normal (L/N) delayed uptake ratio was calculated as: mean counts of tumor ROI (L)/mean counts of normal mirror symmetric ROI (N). (1)H-MRS was performed using a 1.5-T scanner equipped with a spectroscopy package. SPECT and (1)H-MRS results were compared with pathology or follow-up neuroimaging studies. SPECT and (1)H-MRS showed concordant residue or recurrence in 9/24 (37.5%) patients. Both were true negative in 6/24 (25%) patients. SPECT and (1)H-MRS disagreed in 9 recurrences [7/9 (77.8%) and 2/9 (22.2%) were true positive by SPECT and (1)H-MRS, respectively]. Sensitivity of SPECT and (1)H-MRS in detecting recurrence was 88.8 and 61.1% with accuracies of 91.6 and 70.8%, respectively. A positive association between the delayed L/N ratio and tumor grade was found; the higher the grade, the higher is the L/N ratio (r = 0.62, P = 0.001). Tc-99m (V) DMSA brain SPECT is more accurate compared to (1)H-MRS for the detection of tumor residual tissues or recurrence in glioma patients with previous radiotherapy. It allows early and non-invasive differentiation of residual tumor or recurrence from irradiation necrosis.
 ...
PMID:Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results. 2191 37